Stock Market ChatCOMMUNITY + RESEARCHMember login SMC NEWS & MARKET BRIEFINGS
Stock Market Chat reporting built from verified public sources, with direct citations, SMC context, and uncertainty kept visible.
MARKET NEWS
SPY finished up 0.023%, QQQ up 0.016% and IWM was unchanged. The session was marked by very narrow leadership: small‑cap and high relative‑volume breakouts led activity while a confirmed acquisition for Microchip (MCHP) showed up as a tangible catalyst; options flow showed call concentration in SPY/QQQ but confirmation was limited.
Liberty Media Corporation will release third quarter 2026 results before market open on Thursday, November 5, 2026, and will host a conference call the same day at 10:00 a.m. E.T. The company will accept questions on the call and will provide a webcast and archived replay on its investor relations website.
XORTX Therapeutics announced an anticipated Clinical Trial Application planned for filing with Health Canada for XRx-026 (XORLO™), describing a two-part study XRX-OXY-102 that will evaluate their proprietary oxypurinol formulation in gout. The company says conducting part one in Canada is intended to support its planned NDA filing with the U.S. Food and Drug Administration.
Marcus & Millichap says its Preferred Partner relationship with Brown & Brown has expanded into Canada, aiming to give Canadian commercial real estate investors earlier access to insurance, risk and underwriting insights. The release describes services to be offered and reiterates firm-scale metrics for both companies.
Mineralys reported new analyses from its Phase 3 Launch-HTN trial showing that 46% of lorundrostat-treated participants reached office systolic blood pressure <130 mmHg at 12 weeks and that 70% achieved ≥10 mmHg SBP reduction. Separate Phase 2 Explore-OSA results showed an 11.1 mmHg morning SBP reduction at Week 4 with lorundrostat 50 mg and no measurable change in apnea-hypopnea indices; the company reports no significant safety signals.
Profound Medical and Telix Pharmaceuticals announced a co-education agreement to promote PSMA-PET molecular imaging and Profound’s MRI-guided TULSA-PRO platform. The collaboration sets out joint educational initiatives and describes planned software integration work to incorporate PSMA-PET data into Profound’s Treatment Delivery Console.
L3Harris Technologies says NASA selected the company to design, assemble, integrate and test a telescope for the European Space Agency-led Laser Interferometer Space Antenna (LISA) mission. The release describes a ceramic glass telescope and prior prototype work guiding flight-hardware development at NASA’s Goddard Space Flight Center.
MARKET NEWS
SPY and QQQ finished essentially unchanged (SPY +0.03%, QQQ +0.10%) while IWM was flat. The tape was narrow: several small‑cap breakouts, high relative‑volume movers and acquisition/news runners led activity beneath otherwise muted index moves.
bioAffinity Technologies announced a registered direct offering and a concurrent private placement expected to generate approximately $4 million in gross proceeds. The transaction terms include common stock (or pre-funded warrants) priced at $6.122 (or $6.115 per pre-funded warrant) and warrants for up to 980,072 shares exercisable after stockholder approval.
NVIDIA announced commitments valued at $1 billion to support U.S. scientific research and super intelligence over the next five years, targeting areas the company described as critical for U.S. leadership including quantum computing, healthcare and energy security. The company framed the funding as support for higher-education research institutions, quantum investments, and cloud providers serving U.S. government mission needs.
bioAffinity Technologies announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its CyPath Lung method that combines automated flow cytometry and machine learning. The company described the patent as the first in Japan for CyPath Lung driven by an AI-built algorithm and highlighted prior patents and clinical performance metrics for the test.
Cyabra, Inc. (Nasdaq: CYAB) announced an enterprise agreement with a Fortune 500 global media and entertainment conglomerate to deploy its AI narrative intelligence platform to the company's marketing, communications, and security teams. The company says the engagement expands its commercial footprint and validates demand for disinformation security and narrative protection.
Volato Group announced a corporate rebrand to SOAR AI, reflecting a shift to AI infrastructure and software following its merger with Alignment Engine Inc. The company says it has secured approximately $1.2 billion of contracted customer demand for an Ohio AI campus and cites specific GPU deployment orders with aggregate contract values.
Arqit Quantum Inc. released select preliminary unaudited financial results for the second half and full fiscal year 2026, reporting expected revenue ranges and a cash and cash equivalents balance as of 30 September 2026, and describing contract activity that affected and will affect revenue recognition.
MARKET NEWS
Confirmed: Viatris (VTRS) announced an agreement to acquire Pacira BioSciences on Oct. 8, 2026. The company frames the transaction as part of a move to expand its Innovative Medicines portfolio and to position Viatris as a leader in non‑opioid pain therapies.
Byrna Technologies reported fiscal Q3 2026 net revenue of $15.3 million and gross profit of $12.2 million (79% of net revenue), including a one-time $2.3 million tariff refund. The company reported a net loss of $(2.9) million for the quarter, noted adjusted gross margin of approximately 65% excluding the tariff item, and highlighted operational actions including an acquisition, outsourced ammunition production, and marketing initiatives.
MARKET NEWS
Confirmed: Viatris (VTRS) announced an agreement to acquire Pacira BioSciences in a press release dated October 8, 2026. The company describes the transaction as advancing its Innovative Medicines strategy and positioning it as a leader in non‑opioid pain therapies.
Mynd.ai announced that Arthur Giterman will step down as CEO and CFO effective October 11, 2026, and resign from the Board the same day. The Board appointed Bin Shen as Chief Executive Officer and Interim Chief Financial Officer effective October 12, 2026; the company says it will search for a permanent CFO.
USFM Corporation and Twin Vee PowerCats Co. amended their July 12, 2026 definitive merger agreement to change the transaction structure, add a requirement for USFM to seek an up to $5 million PIPE, and adjust the post-closing ownership split to 93% pre-closing USFM stockholders / 7% pre-closing Twin Vee stockholders. The parties expect closing in the fourth quarter of 2026 or the first quarter of 2027, subject to customary conditions.
Apple and The King’s Trust announced the Apple x King’s Trust Creative Labs, an immersive education program in London that will start with a cohort of up to 20 young people ages 18 to 30 and run workshops aligned with the recent opening of Apple Music Hall. The initiative builds on an existing partnership that includes STEAM programming, a 12-week Team program, and commitments to AI literacy resources.
MARKET NEWS
Large-cap tech lagged the session (QQQ -1.5%) while the headline S&P ETF fell modestly (SPY -0.3%) and small‑cap activity picked up. Movers and breakouts were concentrated in high relative‑volume, short‑interest names even as overall breadth remained weak and capital flow was slightly negative.
Profound Medical announced preliminary unaudited third quarter 2026 revenue expected in the range of $9.8 million to $10.0 million, a figure the company says is above Wall Street expectations, with gross margin expected to exceed 70%. The company will report audited results after market close on Thursday, November 5, 2026 and hold a conference call at 4:30 p.m. ET.
MicroVision reiterated full year 2026 revenue guidance of $10 million to $15 million, said it expects revenue to double in 2027, and described commercialization progress across industrial, security and defense, intelligent infrastructure and other markets while pursuing operating efficiencies to reduce cash burn.
MARKET NEWS
Confirmed: ESCO Technologies has closed its largest-ever acquisition, buying Megger for $2.3 billion. The transaction is an acquisition announcement published Oct. 7, 2026; market data do not include share-price or financing details.
Novartis announced FDA approval of Rhapsido (remibrutinib) for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines, based on the SD cohort of the Phase III RemIND trial where Rhapsido produced higher rates of complete hive resolution versus placebo by Week 12. The company reports a safety profile in SD consistent with CSU and no routine laboratory monitoring required.
Ondas Inc. reported securing more than $165 million in aggregate orders between the second half of August and October 1, 2026, bringing orders secured since June 30 to over $270 million when combined with approximately $105 million previously disclosed. The company said order activity was broad-based and that key programs ULTRA and IonStrike advanced through customer validation milestones, expanding backlog and revenue visibility into 2027.
Constellation Brands announced on October 6, 2026 the acquisition of SpikedAde, a spirit-based ready-to-drink (RTD) brand, for $75 million at close plus contingent consideration of up to $278 million payable over five years. Constellation says the deal expands its RTD portfolio into the "Ade" segment and will integrate SpikedAde into its Beer Division.
MARKET NEWS
Caribou Biosciences (CRBU) tumbled in premarket trade after reports that the company has scrapped CAR‑T programs and RBC cut its price target by ~90%. Separately, CRH confirmed an acquisition of aggregate operations in Denmark and Finland — a corporate expansion announcement.
OS Therapies said its wholly-owned subsidiary OS Animal Health (OSAH) received USDA feedback on the commercial development pathway for OST-HER2 in canine osteosarcoma and plans to seek conditional licensure based on existing clinical efficacy data while anticipating additional studies to obtain full licensure.
RenovoRx reported that the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by the University of Vermont testing intra-arterial gemcitabine delivered via the RenovoCath TAMP platform as neoadjuvant therapy in borderline resectable pancreatic ductal adenocarcinoma. The study will assess tumor regression, intraoperative surgical margins, and safety as UVM plans to enroll approximately 10 patients.